Compare MRTN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRTN | DBVT |
|---|---|---|
| Founded | 1946 | 2002 |
| Country | United States | France |
| Employees | N/A | 90 |
| Industry | Trucking Freight/Courier Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 1994 | 2014 |
| Metric | MRTN | DBVT |
|---|---|---|
| Price | $11.62 | $19.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.75 |
| AVG Volume (30 Days) | ★ 539.9K | 218.4K |
| Earning Date | 04-15-2026 | 04-29-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $1,131,455,000.00 | $4,151,000.00 |
| Revenue This Year | N/A | $65.50 |
| Revenue Next Year | $10.12 | $47.02 |
| P/E Ratio | $55.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.35 | $3.91 |
| 52 Week High | $14.19 | $26.19 |
| Indicator | MRTN | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 41.23 |
| Support Level | $11.43 | $8.55 |
| Resistance Level | $12.19 | $24.47 |
| Average True Range (ATR) | 0.44 | 1.50 |
| MACD | -0.19 | -0.35 |
| Stochastic Oscillator | 6.78 | 16.36 |
Marten Transport Ltd is a temperature-sensitive and dry truckload carrier in the United States. The company specializes in transporting and distributing food and other consumer packaged goods that require a temperature-controlled or insulated environment. The company operates through four segments: Truckload, Dedicated, Intermodal, and Brokerage, generating the majority of its revenue from the Truckload segment. The Truckload segment offers a mix of regional short-haul and medium- to long-haul full-load transportation services transporting food and other consumer packaged goods.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.